Na Xu

No.1838 North Guangzhou Avenue
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 142 publications

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

Journal: Hematological oncology
Published: April 27, 2026

Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.

Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.

Journal: Experimental hematology & oncology
Published: March 25, 2026

Donor-derived distinct neutrophil subsets in the G-CSF-mobilized peripheral blood grafts predict acute GVHD development.

Donor-derived distinct neutrophil subsets in the G-CSF-mobilized peripheral blood grafts predict acute GVHD development.

Journal: Transplantation and cellular therapy
Published: March 11, 2026

Safety and Efficacy of Vedolizumab for the Patients With Gastrointestinal Acute Graft-Versus-Host Disease Refractory to Steroid Treatment After Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World, Retrospective Multicenter Study (VAST Study).

Safety and Efficacy of Vedolizumab for the Patients With Gastrointestinal Acute Graft-Versus-Host Disease Refractory to Steroid Treatment After Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World, Retrospective Multicenter Study (VAST Study).

Journal: MedComm
Published: December 31, 2025

Successful treatment of relapsed KMT2A rearranged AML with central nervous system involvement using revumenib in combination with venetoclax and azacitidine: A case report.

Successful treatment of relapsed KMT2A rearranged AML with central nervous system involvement using revumenib in combination with venetoclax and azacitidine: A case report.

Journal: Therapeutic advances in hematology
Published: November 13, 2025

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia.

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 05, 2025

Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Journal: Blood cancer journal
Published: October 22, 2025

GZMK-expressing tissue-resident memory CD8+ T cells participate in human intestinal acute graft-versus-host disease.

GZMK-expressing tissue-resident memory CD8+ T cells participate in human intestinal acute graft-versus-host disease.

Journal: JCI insight
Published: August 14, 2025

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Journal: Blood advances
Published: August 01, 2025

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Journal: Biomarker research
Published: June 24, 2025

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

Journal: The Lancet. Haematology
Published: June 11, 2025

Increased EBV infection and relapse following haploidentical hematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis: a propensity score matching analysis.

Increased EBV infection and relapse following haploidentical hematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis: a propensity score matching analysis.

Journal: Frontiers in cellular and infection microbiology
Published: June 02, 2025
Showing 1-12 of 142

Last Updated: 09/26/2026